Vertex Pharma (VRTX) Tops Q4 EPS by 26c; Guides FY Revenue

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Vertex Pharma (VRTX) Tops Q4 EPS by 26c; Guides FY Revenue

Vertex Reports Fourth Quarter and Full Year Financial 2022 Results

February 7, 2023 4:01 PM EST

Full year product revenue of $8.93 billion, an 18% increase compared to full year 2021

Full year GAAP and non-GAAP net income increased 42% and 53%, respectively, versus 2021

Company provides full year 2023 product revenue guidance of $9.55 to $9.7 billion

Exa-cel regulatory submissions validated in the EU and U.K.; U.S. rolling BLA submission underway

Advancing broad and diverse clinical pipeline, with multiple clinical milestones expected in 2023

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the... More